Effect of berberine on glucolipid metabolization in diabetic skeletal muscle and its mechanism

Abstract

Abstract:

Aim To investigate the effect of berberine on damaged morphology and glucolipid metabolization in skeletal muscle of diabetic rat and the relationship between peroxisome proliferator-activated receptor (PPARs) α/γ/δ protein expression. Methods Type 2 diabetes mellitus rats were induced by an injection of 35 mg·kg^-1 streptozotocin (STZ) and a high-carbohydrate/high-fat diet for 16 weeks. From week 17 to 32, diabetic rats were given low-, middle-, high-dose berberine (75, 150, 300 mg·kg^-1), fenofibrate (100 mg·kg^-1) and rosiglitazone (4 mg·kg^-1) by oral administration, respectively. The skeletal muscle structure was observed with hematoxylin-eosin (HE) staining, glycogen and triglyceride contents were measured by spectrophotometry and PPAR α/γ/δ protein expressions were detected by immunohistochemistry. Results Fiber distribution remained normal in skeletal muscles of all the groups, middle-, high-dose berberine partly improved diabetic fibre atrophy, increased glycogen and decreased triglyceride levels in diabetic muscle (P < 0.01). Middle-, high-dose berberine and rosiglitazone all significantly reduced PPARγ protein level in diabetic skeletal muscle (P < 0.01); middle-, high-dose berberine and fenofibrate strikingly increased both PPARα and PPARδ expression (P < 0.01). Conclusion Berberine modulates PPAR α/γ/δ protein expression in diabetic skeletal muscle which may contribute to ameliorate fibre damage and glucolipid metabolization.

Key words: Berberine, Berberine, PPAR α/γ/δ, PPAR α/γ/δ, Skeletal muscle, Skeletal muscle, Glucolipid metabolization, Glucolipid metabolization

CLC Number:

R965

Supporting:

Ji-Yin Zhou, Shi-Wen Zhou^*. Effect of berberine on glucolipid metabolization in diabetic skeletal muscle and its mechanism[J]. .

References

[1] The diabetes control and complications trial research group. TDCaCTR. N. Engl. J. Med. 1993, 329 (14): 977–986.
[2] UK prospective diabetes study (UKPDS) group. Lancet. 1998, 352 (9131): 837–853.
[3] Peter, P.; Nuttall, S.L.; Kendall, M.J. J. Clin. Pharm. Ther. 2003, 28: 167–174.
[4] Taskinen, M.R. Atheroscler. Suppl. 2002, 3(1): 47–51.
[5] Berger, J.; Moller, D.E. Annu. Rev. Med. 2002, 53: 409–435.
[6] Inzucchi, S.E. Jama. 2002, 287 (3): 360–372.
[7] Kim, Y.Y.; Kang, H.J.; Ko, S.K.; Chung, S.H. Arch. Pharm. Res. 2002, 25(6): 923–931.
[8] Altern. Med. Rev. 2000, 5(2): 175–177.
[9] Leng, S.H.; Lu, F.E, Xu, L.J. Acta Pharm. Sin. 2004, 25(4): 496–502.
[10] Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; Wang, S.; Wu, J.; Wang,Y.; Li, Z.; Liu, J.; Jiang, J.D. Nat. Med. 2004, 10 (12): 1344–1351.
[11] Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C.L.; Ramarao, P. Pharm. Res. 2005, 52(4): 313–320.
[12] Oakes, N.D.; Thalen, P.G.; Jacinto, S.M.; Ljung, B. Diabetes. 2001, 50(5): 1158–1165.
[13] Xie, W.; Xing, D.; Sun, H.; Wang, W.; Ding, Y.; Du, L. Am. J. Chin. Med. 2005, 33(1): 95–105.
[14] Khan, M.A.; St Peter, J.V.; Xue, J.L. Diabetes Care. 2002, 25(4): 708–711.
[15] Schoonjans, K.; Staels, B.; Auwerx, J. Biochim. Biophys. Acta. 1996, 1302(2): 93–109.
[16] Schoonjans, K.; Staels, B.; Auwerx, J. J. Lipid Res. 1996, 37(5): 907–925.
[17] Oliver, W.R. Jr.; Shenk, J.L.; Snaith, M.R.; Russell, C.S.; Plunket, K.D.; Bodkin, N.L.; Lewis, M.C.; Winegar, D.A.; Sznaidman, M.L.; Lambert, M.H.; Xu, H.E.; Sternbach, D.D.; Kliewer, S.A.; Hansen, B.C.; Willson, T.M. Proc. Natl. Acad. Sci. USA. 2001, 98(9): 5306–5311.
[18] Luquet, S.; Gaudel, C.; Holst, D.; Lopez-Soriano, J.; Jehl-Pietri, C.; Fredenrich, A.; Grimaldi, P.A. Biochim. Biophys. Acta. 2005, 1740(2): 313–317.
[19] Huang, C.; Zhang, Y.; Gong, Z.; Sheng, X.; Li, Z.; Zhang, W.; Qin, Y. Biochem. Biophys. Res. Commun. 2006, 348(2): 571–578.
[20] Brusq, J.M.; Ancellin, N.; Grondin, P.; Guillard, R.; Martin, S.; Saintillan, Y.; Issandou, M. J. Lipid. Res. 2006, 47(6): 1281–1288.
[21] Lee, Y.S; Kim, W.S.; Kim, K.H.; Yoon, M.J.; Cho, H.J.; Shen, Y.; Ye, J.M.; Lee, C.H.; Oh, W.K.; Kim, C.T.; Hohnen-Behrens, C.; Gosby, A.; Kraegen, E.W.; James, D.E.; Kim, J.B. Diabetes. 2006, 55(8): 2256–2264.
[22] Cossel, L.; Schneider, E.; Kuttler, B.; Schmidt, S.; Wohlrab, F.; Schade, J.; Bochmann, C. Exp. Clin. Endocrinol. 1985, 85(1): 7–26.
[23] Ar’ Rajab, A.; Ahrén, B. Pancreas. 1993, 8(1): 50–57.
[24] Eriksson, U.J.; Borg, L.A.; Forsberg, H.; Styrud, J. Diabetes. 1991, 40(2): 94–98.
[25] Ye, J.M.; Doyle, P.J.; Iglesias, M.A.; Watson, D.G.; Cooney, G.J.; Kraegen, E.W. Diabetes. 2001, 50(2): 411–417.
[26] Koh, E.H.; Kim, M.S.; Park, J.Y.; Kim, H.S.; Youn, J.Y.; Park, H.S.; Youn, J.H.; Lee, K.U. Diabetes. 2003, 52 (9): 2331–2337.